GeriQBank · Paper III · Q9
Benign / essential tremor — presentation, differential diagnosis and treatment
- Chapter
- Parkinson's Disease & Movement Disorders
- Years asked
- Not recorded in the source
- Frequency
- Set 2× in Paper III and Paper IV (2009–2025)
As set in the university papers — 2 wordings
Benign essential tremor — clinical presentation, differential diagnosis and treatment.
Paper III · Parkinson’s Disease & Movement Disorders · asked ×1 · 7-mark note · see in paper list
Differential diagnosis of tremor in the older person. Discuss the treatment modalities for each of these conditions.
Paper IV · Neurology · asked ×1 · 7-mark note · see in paper list
Answer framework
- Definition and epidemiology — the commonest movement disorder; prevalence rising with age; other tremors often misdiagnosed as ET
- Pathophysiology — tremor networks; the basal ganglia trigger tremor and the cerebellum modulates amplitude
- Presentation — action tremor; features for and against ET; alcohol, coffee and family history
- Differential diagnosis — parkinsonian, dystonic (spiral test), cerebellar, functional, drug-induced and other causes
- Investigation — usually clinical; bloods and thyroid; EMG and DaTSCAN in difficult cases
- Treatment — treat only functional or social impairment; propranolol and primidone; second-line drugs; surgery
- Recent updates — staged bilateral MRgFUS, comparison with DBS, MDS classification and "ET plus", Indian context
An exam answer plan drawn from the detailed answer below. Use it to attempt the question first.
Detailed answer
Pro · free in betaAttempt it firstOutline your answer as a 7-mark note before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer
Short revision answer
- Essential tremor (ET) is the commonest movement disorder: up to 3% of the population, 5% of those over 60 and 21.7% of those over 95. Dystonic and parkinsonian tremors are often misdiagnosed as ET.
- Tremor arises from networks linking the inferior olive, cerebellum, thalamus, basal ganglia and cortex. The basal ganglia trigger tremor and the cerebellum (affected in ET) modulates its amplitude.
- ET is a bilateral (possibly asymmetric) postural and kinetic tremor; intention tremor, or a kinetic tremor larger than the postural one, favours ET. Rest tremor suggests parkinsonism; unilateral tremor suggests parkinsonian, dystonic or task-specific tremor; isolated or early head tremor suggests dystonia. Response to alcohol and a family history are not unique to ET.
- Differentials: parkinsonian tremor (rest tremor, rigidity, bradykinesia); dystonic tremor (posturing, geste antagoniste, directional head tremor; multi-axis spirals versus single-axis spirals in ET); cerebellar tremor (intention tremor with ataxia — MRI needed); functional tremor (variability, distractibility, entrainment); hyperthyroidism, orthostatic tremor and Wilson's disease.
- Drug-induced tremor is common with polypharmacy: caffeine, beta-agonists, theophylline, tricyclics, lithium, SSRIs, neuroleptics, valproate, amiodarone, ciclosporin, tacrolimus and metoclopramide — stop them if possible.
- Diagnosis is usually clinical; check basic bloods, liver function and thyroid function. EMG helps in orthostatic tremor; DaTSCAN is normal in ET and abnormal in parkinsonism.
- There is no cure, so treat only if the tremor impairs function or social life. First line: propranolol or primidone (30–70% amplitude reduction), often stopped for side effects (bradycardia, bronchospasm, hypotension and masked hypoglycaemia with propranolol; nausea and drowsiness with primidone). Second line: topiramate, gabapentin, benzodiazepines.
- Refractory tremor: Vim thalamic DBS, gamma knife or focused ultrasound thalamotomy. Staged bilateral MRgFUS is now FDA-approved (second side at least 9 months later; JAMA Neurology 2024) and appears comparable to bilateral DBS, but can impair gait and balance.
- The MDS two-axis classification defines "essential tremor plus". In India, propranolol and primidone are cheap and MRgFUS is scarce; check for Wilson's disease (ceruloplasmin, 24-hour urinary copper, slit lamp) when tremor is atypical.
Condensed by GeriClinics from the detailed answer below, with no new facts added.
High-Yield Points (Textbook)
Source: Pathy's 6th ed., Chapter 54 (Non-Parkinsonian movement disorders in the elderly), Tables 54.3 and 54.4; Chapter 53.
Definition and epidemiology
Essential tremor (ET) is the most common tremor disorder and the most common movement disorder, with an estimated prevalence of up to 3% in the general population and up to 5% in adults over 60.
ET becomes more common with age — in one study the prevalence in adults over 95 was as high as 21.7%.
Tremor of some kind is near-universal: an estimated 98.9% prevalence in a large population study, the overwhelming majority being physiological.
Other tremor disorders are less common and are often missed or misdiagnosed as essential tremor — especially dystonic tremor and parkinsonian tremor.
Pathophysiology
The exact mechanism is unknown, but tremor disorders arise from dysfunction in networks involving the inferior olive, cerebellum, thalamus, basal ganglia and cortex.
Current theory: the basal ganglia network triggers the onset of tremor, while the cerebellar network — predominantly affected in essential tremor — modulates its amplitude. Which part of the network is affected determines the phenomenology — rest tremor in PD, action-induced tremor in ET.
Because tremor arises from dysfunctional CNS networks, tremor disorders form a spectrum with overlapping clinical features.
Presentation
ET is an action-induced (postural and kinetic) tremor. Features making ET more likely are the presence of an intention tremor and an action-induced kinetic tremor of greater amplitude than the postural tremor.
Rest tremor is not a typical feature of ET and renders a diagnosis of parkinsonism more likely.
ET may be asymmetric but is usually not unilateral; unilateral tremor is more commonly parkinsonian, dystonic or task-specific.
An isolated head tremor, or head tremor that started before other body parts, points away from ET and towards dystonia.
Ethanol can improve the tremor, but this is not unique to ET and also occurs in dystonia. Increased coffee intake and smoking may cause or worsen tremor.
A strong family history of tremor is often found in ET, but may also occur in dystonia (for example in certain Jewish populations).
Differential diagnosis
Parkinsonian tremor — look for rest tremor with rigidity, bradykinesia and postural instability, plus minor signs such as hypomimia, loss of prosody and camptocormia. Note that slow/rapid alternating movements without decrement, and reduced arm swing, can also occur in dystonia and ET.
Dystonic tremor — abnormal posturing such as spooning of the hand, abnormal posturing or flexion of the thumb or hand; focal muscle hypertrophy, torticollis or a geste antagoniste; the tremor may be arrhythmic, and dystonic head tremor may be directional. Voice tremor with voice breaks and a spasmodic quality suggests dystonia.
The spiral test is a valuable and easy clinic test: patients with ET draw spirals with one clear single axis, whereas dystonic tremor spirals typically have multiple axes or no clear axis at all.
Cerebellar tremor — intention tremor accompanied by dysmetria, scanning speech, saccadic eye movement abnormalities and truncal ataxia. MRI with and without contrast is required, since a mass, stroke or multiple sclerosis may cause secondary tremor.
Functional tremor — features of variability, distractibility, entrainment and suggestibility.
Drug-induced tremor is especially important in the elderly with polypharmacy. Common culprits: caffeine, ethanol, nicotine, beta-adrenergic agonists (albuterol, salmeterol), tricyclic antidepressants, lithium, SSRIs, neuroleptics, valproate, amiodarone, ciclosporin, tacrolimus and metoclopramide; Chapter 53 adds bronchodilators and theophylline. The medication list must be scrutinised and any tremorogenic drug stopped if possible.
Other causes: hyperthyroidism (recognised by other signs and TSH estimation), orthostatic tremor, late-onset Wilson's disease (rare in the elderly but considered in complex cases), and the extrapyramidal syndrome of ageing.
Investigation
In most cases of tremor in the elderly no further workup is required — history and examination are sufficient to establish the diagnosis. Basic blood work, liver function tests and thyroid studies can at times be helpful.
EMG is very beneficial for diagnosing orthostatic tremor. DaTSCAN is normal in ET and abnormal in PD and other parkinsonian syndromes, and may establish the correct diagnosis in difficult cases.
Treatment
There is no curative therapy for essential tremor, and the indication for symptomatic therapy depends solely on the functional and social impairment the patient experiences — a critical geriatric principle.
First-line pharmacotherapy: propranolol and primidone, which induce a 30–70% reduction in tremor amplitude.
Both cause significant side effects leading to frequent discontinuation — bradycardia with propranolol; nausea, dizziness and drowsiness with primidone. In older patients also consider bronchospasm, hypotension and masking of hypoglycaemia with propranolol.
Second-line: topiramate, gabapentin and benzodiazepines.
Surgical therapy gives a more pronounced reduction of tremor amplitude than drugs: deep brain stimulation with the typical target being the ventral intermediate (Vim) nucleus of the thalamus, gamma knife surgery, and focused ultrasound thalamotomy. Given their invasive nature, these are reserved for patients with severe tremor refractory to medication.
Latest Updates (2023–Present)
Staged bilateral MRgFUS thalamotomy is now approved. The FDA approved staged bilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor, with the second side treated at least nine months after the first. The pivotal open-label trial was published by Kaplitt, Krishna, Eisenberg, Elias and colleagues in JAMA Neurology 2024.
Efficacy comparable to bilateral DBS. A 2025 Movement Disorders analysis found the efficacy of bilateral MRgFUS and bilateral DBS to be comparable, and probabilistic lesion mapping identified two sweet spots — the dorsal Vim–Vop border and the ventral Vim/posterior subthalamic area. A prospective series in Brain Communications 2025 (20 patients, 6-month follow-up on the Clinical Rating Scale for Tremor) confirmed benefit, with balance and gait impairment as the adverse events to counsel about — particularly relevant to falls risk in the elderly. Classification has changed. The MDS consensus classification of tremor uses two axes — clinical characteristics and aetiology — and introduces the category "essential tremor plus" for isolated tremor with additional soft neurological signs (mild dystonic posturing, impaired tandem gait, questionable rest tremor). Pathy's Chapter 54 already uses the phrase "ET or ET plus" without defining it. Position statement: the American Society for Stereotactic and Functional Neurosurgery position statement on MRgFUS for essential tremor (Neurosurgery 2020) remains the reference document; in the USA all treatment sites are approved for Medicare payment. Indian context: propranolol and primidone are inexpensive and widely available; topiramate and gabapentin are readily obtainable. MRgFUS is available in a small number of Indian tertiary centres (and is costly and largely out-of-pocket), so DBS and stereotactic thalamotomy remain the practical surgical options for refractory tremor in most of the country. In differential diagnosis, remember that Wilson's disease is relatively more common in India and presents at a younger age, so serum ceruloplasmin, 24-hour urinary copper and slit-lamp examination should be checked in any tremor with atypical features, hepatic disease or psychiatric symptoms.
Current Practice Update
Aspect Textbook position (Pathy's 6th ed.) Current evidence-based practice Nomenclature "Essential tremor" (with the phrase "ET or ET plus" Formal MDS two-axis classification with a defined used in passing) "essential tremor plus" category First-line drugs Propranolol and primidone, 30–70% amplitude Unchanged — still first line, and still frequently reduction discontinued for side effects Focused ultrasound Mentioned as a newer option for refractory tremor Staged bilateral MRgFUS is FDA-approved, second side at least 9 months after the first (JAMA Neurology 2024)
MRgFUS vs DBS Both listed as options for refractory tremor Efficacy appears comparable; MRgFUS is incisionless but lesional and irreversible, with gait and balance adverse effects Indication to treat Depends solely on functional and social impairment Unchanged — and reinforced as a geriatric principle: treat disability, not the tremor amplitude Examiner's Tip — lines that earn marks Lead with epidemiology: "the most common movement disorder — up to 3% of the population, up to 5% over 60, and as high as 21.7% over 95."
State the network theory: "the basal ganglia network triggers tremor onset while the cerebellar network, predominantly affected in ET, modulates amplitude."
Contrast in one line: "rest tremor in Parkinson's disease, action-induced tremor in essential tremor" — and add that DaTSCAN is normal in ET.
Name the spiral test — single axis in ET, multiple or no axis in dystonic tremor. Examiners love this because it is a bedside test. State the treatment principle verbatim: "There is no curative therapy, and the indication for symptomatic treatment depends solely on the functional and social impairment the patient experiences."
Finish the ladder: propranolol/primidone → topiramate, gabapentin, benzodiazepines → Vim DBS, gamma knife or focused ultrasound thalamotomy for refractory cases.
Cross-cutting revision aid — the night before the examination One-line signatures to recall under pressure Condition The line that identifies it Parkinson's disease Asymmetric onset, rest tremor, excellent sustained levodopa response, dementia only after years Progressive supranuclear palsy Symmetric, no tremor, early falls, downgaze palsy, axial rigidity, levodopa-unresponsive, convex midbrain on MRI Multiple system atrophy Early severe dysautonomia with pyramidal or cerebellar signs Corticobasal degeneration Alien hand, myoclonus, dystonia, cortical sensory loss Dementia with Lewy bodies Dementia within months of parkinsonism, hallucinations, fluctuation, neuroleptic sensitivity Vascular parkinsonism Onset or worsening within one month of stroke; multilacunar state; pseudobulbar features Drug-induced parkinsonism Neuroleptic exposure, dyskinesia frequent, no tremor, normal DaTSCAN, 20% persist after withdrawal Normal pressure hydrocephalus Gait + incontinence + cognitive slowing; ventriculomegaly out of proportion to atrophy; no tremor or rigidity Essential tremor Bilateral action tremor, family history, alcohol-responsive, normal DaTSCAN, single-axis spiral Numbers most likely to be asked PD prevalence ~1% over age 65; median age at diagnosis 60; mean survival from diagnosis 15 years; family history in 6–10%. Non-PD causes of very late-onset parkinsonism: 20–40%. Persistent signs after stopping the offending drug: 20%. Levodopa 300–600 mg/day in early disease; challenge dose 150–250 mg; rest tremor frequency 4–6 Hz. Depression in PD ~50%; constipation ~50%; delayed gastric emptying ≥70%; parkinsonism in Alzheimer's disease ~15%. Orthostatic hypotension: ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes. Clozapine stop threshold: neutrophils <1500/mm3. Essential tremor: 3% general population, 5% over 60, 21.7% over 95; propranolol/primidone reduce amplitude by 30–70%. PSP: prevalence 5–6.4/100,000; survival PSP-RS 5–7 years, PSP-P 8–12 years.
India: PD crude prevalence 7–60/100,000, age-adjusted 53–192/100,000; Parsi community of Mumbai 328/100,000 (not generalisable); parkinsonism in Bangalore old-age homes 17.8%.
Dates and approvals worth quoting (2024–2026)
February 2024 — NSD-ISS and SynNeurGe biological frameworks published together in Lancet Neurology. August 2024 — Crexont (IPX203 extended-release carbidopa/levodopa) FDA-approved. September 2024 — staged bilateral MRgFUS thalamotomy trial for essential tremor published in JAMA Neurology. October 2024 — Vyalev (foslevodopa/foscarbidopa), first 24-hour subcutaneous levodopa infusion, FDA-approved. February 2025 — Medtronic BrainSense Adaptive DBS FDA-approved on ADAPT-PD; Onapgo subcutaneous apomorphine infusion FDA-approved; Exenatide-PD3 published negative in The Lancet.
September 2025 — tavapadon (D1/D5 partial agonist) NDA submitted on the TEMPO Phase 3 programme. March 2026 — FDA label warning for vitamin B6 deficiency and seizures across all carbidopa/levodopa products. June 2026 — The Lancet issued an Expression of Concern regarding the Exenatide-PD3 publication.
How was your recall?
Rating marks the question complete. “Need another pass” also adds it to your bookmarks.
References
- PAPERS-2-3-4_COMBINED.pdf — page 569
- GeriQBank source PDF — p. 569
Spotted an error or something out of date?Report a problem with this page